We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CB:NYSEChubb Limited Analysis

Data as of 2026-05-25 - not real-time

$327.89

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Chubb Limited (CB) is trading at $327.89, comfortably above its 20‑day (324.70) and 50‑day (326.34) simple moving averages, indicating short‑term momentum. The MACD histogram is positive (0.96) and the signal line is bearish, yielding a bullish MACD signal, while the RSI sits at a neutral 53, suggesting room for further upside. Technical support sits near $315 and resistance near $334, placing the current price just below the next resistance level. Fundamentally, the stock trades at a forward PE of 11.2 versus an industry average of 16.8, highlighting a clear value discount. Revenue grew 10.2% YoY, margins remain solid (gross 31%, operating 20.6%, profit 18.5%) and free cash flow exceeds $12.6 B, underscoring robust profitability. The dividend has been raised 5.2% to $4.08 with a low payout ratio of 13.7%, supporting a sustainable 1.24% yield.
A recent $1 B senior note issuance at 5.30% and a $7.5 B share‑repurchase program signal confidence from management and provide additional capital flexibility. Shareholder sentiment is reinforced by a headline naming CB as a top fundamental stock among billionaires, adding qualitative momentum. The DCF‑derived fair value of $605.6 implies an upside of roughly 5% relative to current pricing, while the analyst consensus target median of $340 suggests modest near‑term appreciation. Beta is near zero and 30‑day volatility is moderate at 16.7%, indicating limited price swings in the broader market context. With a strong balance sheet—$7.5 B cash versus $25.1 B debt and a debt‑to‑equity of 31.5%—the company is well‑positioned to weather underwriting cycles. Overall, the combination of undervaluation, dividend stability, and defensive industry characteristics makes CB a compelling buy across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and price above short‑term SMAs
  • Support near $315 with resistance at $334 offering upside
  • Strong dividend increase and low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Consensus target median $340 indicating near‑term upside
  • $7.5 B share buyback enhancing shareholder returns
  • Revenue growth ~10% and solid cash generation

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • DCF fair value $605 suggests long‑term undervaluation
  • Sustainable dividend with low payout and growth
  • Defensive insurance sector with low beta and strong balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth10.20%
Profit Margin18.53%
P/E Ratio11.6
ROE15.43%
ROA3.36%
Debt/Equity31.46
P/B Ratio1.7
Op. Cash Flow$15.2B
Free Cash Flow$12.6B
Industry P/E16.8

Technical Analysis

TrendNeutral
RSI53.0
Support$315.04
Resistance$334.03
MA 20$324.70
MA 50$326.34
MA 200$304.22
MACDBullish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair Value$605.61
Target Price$345.26
Upside/Downside5.30%
GradeUndervalued
TypeBlend
Dividend Yield1.24%

Risk Assessment

Beta-0.05
Volatility16.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.